First was a phase 2 study in which Libtayo was used to treat advanced CSCC. In this investigation, 16% of patients who took Libtayo had a complete response, and 30% demonstrated a partial response. The average response time was just two months. For advanced cancer, the complete response rate shown here is very, very good.